Phytopharmaceuticals Regulatory requirements and licensing process
Abstract
Since the ancient period, people have used herbal treatments for a wide variety of medical issues. In developing countries, most people utilize herbal remedies to cure a variety of diseases. India, the nation that produces the most medicinal plants, is referred to as the botanical garden of the world. Indian drug regulators are focused on quality in order to uphold the standards for herbal remedies, but manufacturers are struggling to satisfy the higher standards. There are difficulties with standardization, finished formulations, and industry-wide evidence-based practices for AYUSH medicines in India. Phytopharmaceuticals, a modern subclass of medications, contain an enriched fraction with at least four distinct chemical markers with one biomarker. The Central Drugs Standards Control Organization (CDSCO) oversees Phytopharmaceuticals. The Ministry of Health and Family Welfare has released a Gazette Notification GSR 918(E)-Schedule Y, Appendix I(B) regarding Phytopharmaceuticals. This new rule is anticipated to encourage new medication discoveries and evolution using botanicals in a scientific manner and would aid in the modern medical profession's acceptance of Phytopharmaceuticals as a significant alternative to allopathic modern medicine. Phytopharmaceuticals are a well-balanced approach that believes in everything but places emphasis on the revalidation of the plant material's specification, in contrast to conventional pharmaceuticals that suspect everything and AYUSH medicines that trust everything. The purpose of this article is to give specific detail and compiled knowledge about Phytopharmaceutical medicines, regulatory requirements, and regulatory processes.
Downloads
References
2. Introduction and importance of medicinal plantsand herbs. National Health Portal (NHP), India [Internet]. 2022 Nov [cited 2023 Jun 05]. Available from:
https://www.nhp.gov.in/introduction-and-importance-of-medicinal-plants-and-herbs_mtl.
3. WHO, “General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine” [Internet]. 2022 Nov [cited 2023 Jul 02]. Available from:
https://apps.who.int/iris/bitstream/handle/10665/66783/WHO_EDM_TRM_2000.1.pdf?sequence=1&isAllowed=y.
4. Singh, Abhishek, et al. "Opportunities and Challenges in Development of Phytopharmaceutical Drug in India-A SWOT Analysis." Journal of Young Pharmacists. 2019;11(3):322.
5. Chauhan, Durgesh Nandini, and Kamal Shah, eds. Phytopharmaceuticals: Potential Therapeutic Applications. John Wiley & Sons; 2021.
6. Sapoliya NK, Mamta B Shah. Regulations on Herbal Products in India, United States and European Union: A Review. Int J Drug Reg Affairs [Internet]. 2022 Jun. 19 [cited 2023 Jul.7];10(2):67-2. Available from:
https://ijdra.com/index.php/journal/article/view/528
7. Nirmal, Puneet, et al. "Phytopharmaceutical regulated new class: An Industrial initiative of Ayurvedic drugs towards the advancement of India system of medicine. "World Journal of Advanced Research and Reviews. 2022;15(3):407-419.
8. Bhusnure, Omprakash G., et al. "Phytopharmaceuticals: An emerging platform for innovation and development of new drugs from botanicals."Journal of Drug Delivery and Therapeutics. 2019;9(3):1046-1057.
9. Sharma, Sanjay. "Current status of herbal product: regulatory overview."Journal of pharmacy & bioallied sciences. 2015;7(4):293.
10. CDSCO. "Ministry of Health and Family Welfare notification G.S.R. 918 New Delhi” [Internet]. 2015 Nov [cited 2023 Apr 05]. Available from:
https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTA3MA.
11. CDSCO. "Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs" [Internet]. 2022 Nov [cited 2023 Jun 20]. Available from:
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/New-Drugs/FAQs/New_Drugs_FAQs.doc
12. Agarwal A. “CDSA-Development path of Phytopharmaceuticals -Regulatory Workshop on Phytopharmaceuticals.”
13. Gyllenhaal, C., et al. "Ethnobotanical approach versus random approach in the search for new bioactive compounds: support of a hypothesis."Pharmaceutical biology. 2012;50(1):30-41.
14. Birdi, Tannaz J., S. Brijesh, and P. G. Daswani. "Approaches towards the preclinical testing and standardization of medicinal plants."Foundation for Medical Research India; 2006.
15. Bhatt, Arun. "Phytopharmaceuticals: A new drug class regulated in India."Perspectives in clinical research. 2016;7(2):59.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
